98 related articles for article (PubMed ID: 4028024)
21. The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.
Brown MP; Bezak E; Allen BJ
Melanoma Manag; 2015 Nov; 2(4):353-366. PubMed ID: 30190863
[TBL] [Abstract][Full Text] [Related]
22. Proteoglycans-Biomarkers and Targets in Cancer Therapy.
Nikitovic D; Berdiaki A; Spyridaki I; Krasanakis T; Tsatsakis A; Tzanakakis GN
Front Endocrinol (Lausanne); 2018; 9():69. PubMed ID: 29559954
[TBL] [Abstract][Full Text] [Related]
23. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.
Seliger B; Kloor M; Ferrone S
Oncoimmunology; 2017; 6(2):e1171447. PubMed ID: 28344859
[TBL] [Abstract][Full Text] [Related]
24. Cell adhesion to anosmin via α5β1, α4β1, and α9β1 integrins.
Endo Y; Ishiwata-Endo H; Yamada KM
Cell Adh Migr; 2018 Mar; 12(2):93-100. PubMed ID: 27715389
[TBL] [Abstract][Full Text] [Related]
25. CD147 and matrix-metalloproteinase-2 expression in metastatic and non-metastatic uveal melanomas.
Lüke J; Vukoja V; Brandenbusch T; Nassar K; Rohrbach JM; Grisanti S; Lüke M; Tura A
BMC Ophthalmol; 2016 Jun; 16():74. PubMed ID: 27255356
[TBL] [Abstract][Full Text] [Related]
26. Sarcoma immunotherapy: past approaches and future directions.
D'Angelo SP; Tap WD; Schwartz GK; Carvajal RD
Sarcoma; 2014; 2014():391967. PubMed ID: 24778572
[TBL] [Abstract][Full Text] [Related]
27. HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes?
Campoli M; Fitzpatrick JE; High W; Ferrone S
J Am Acad Dermatol; 2012 Jun; 66(6):911-6, 916.e1-8. PubMed ID: 22445792
[TBL] [Abstract][Full Text] [Related]
28. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition.
Campoli M; Ferrone S
Semin Immunopathol; 2011 Jul; 33(4):321-34. PubMed ID: 21523560
[TBL] [Abstract][Full Text] [Related]
29. A role for the NG2 proteoglycan in glioma progression.
Stallcup WB; Huang FJ
Cell Adh Migr; 2008; 2(3):192-201. PubMed ID: 19262111
[TBL] [Abstract][Full Text] [Related]
30. The role of the extracellular matrix in angiogenesis in malignant glioma tumors.
Wang D; Anderson JC; Gladson CL
Brain Pathol; 2005 Oct; 15(4):318-26. PubMed ID: 16389944
[TBL] [Abstract][Full Text] [Related]
31. Human uveal melanoma expresses NG2 immunoreactivity.
Li Y; Madigan MC; Lai K; Conway RM; Billson FA; Crouch R; Allen BJ
Br J Ophthalmol; 2003 May; 87(5):629-32. PubMed ID: 12714409
[TBL] [Abstract][Full Text] [Related]
32. The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2.
Barritt DS; Pearn MT; Zisch AH; Lee SS; Javier RT; Pasquale EB; Stallcup WB
J Cell Biochem; 2000 Aug; 79(2):213-24. PubMed ID: 10967549
[TBL] [Abstract][Full Text] [Related]
33. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors.
Shoshan Y; Nishiyama A; Chang A; Mörk S; Barnett GH; Cowell JK; Trapp BD; Staugaitis SM
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10361-6. PubMed ID: 10468613
[TBL] [Abstract][Full Text] [Related]
34. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.
Alpaugh RK; von Mehren M; Palazzo I; Atkins MB; Sparano JA; Schuchter L; Weiner LM; Dutcher JP
Med Oncol; 1998 Sep; 15(3):191-8. PubMed ID: 9819796
[TBL] [Abstract][Full Text] [Related]
35. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.
van den Oord JJ; Paemen L; Opdenakker G; de Wolf-Peeters C
Am J Pathol; 1997 Sep; 151(3):665-70. PubMed ID: 9284814
[TBL] [Abstract][Full Text] [Related]
36. Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes.
Yamashiro S; Okada M; Haraguchi M; Furukawa K; Lloyd KO; Shiku H; Furukawa K
Glycoconj J; 1995 Dec; 12(6):894-900. PubMed ID: 8748167
[TBL] [Abstract][Full Text] [Related]
37. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection.
Lotze MT; Carrasquillo JA; Weinstein JN; Bryant GJ; Perentesis P; Reynolds JC; Matis LA; Eger RR; Keenan AM; Hellström I
Ann Surg; 1986 Sep; 204(3):223-35. PubMed ID: 3753057
[TBL] [Abstract][Full Text] [Related]
40. A transformation-associated 130-kD cell surface glycoprotein is growth controlled in normal human cells.
Klein CE; Ozer HL; Traganos F; Atzpodien J; Oettgen HF; Old LJ
J Exp Med; 1988 May; 167(5):1684-96. PubMed ID: 3259255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
